Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] jumped around 0.19 points on Thursday, while shares priced at $9.24 at the close of the session, up 2.15%.
Compared to the average trading volume of 1.55M shares, AUPH reached a trading volume of 5559231 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Aurinia Pharmaceuticals Inc [AUPH]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $11.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Aurinia Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 30, 2025. The new note on the price target was released on November 04, 2022, representing the official price target for Aurinia Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $34 to $25, while Cantor Fitzgerald kept a Overweight rating on AUPH stock. On December 10, 2021, analysts decreased their price target for AUPH shares from 33 to 31.
The Price to Book ratio for the last quarter was 3.64, with the Price to Cash per share for the same quarter was set at 2.32. Price to Free Cash Flow for AUPH in the course of the last twelve months was 19.79 with Quick ratio for the last quarter at 5.26.
How has AUPH stock performed recently?
Aurinia Pharmaceuticals Inc [AUPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.93. With this latest performance, AUPH shares gained by 23.60% in over the last four-week period, additionally plugging by 13.57% over the last 6 months – not to mention a rise of 2.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUPH stock in for the last two-week period is set at 62.25, with the RSI for the last a single of trading hit 0.43, and the three-weeks RSI is set at 0.38 for Aurinia Pharmaceuticals Inc [AUPH]. The present Moving Average for the last 50 days of trading for this stock 8.33, while it was recorded at 9.01 for the last single week of trading, and 8.19 for the last 200 days.
Aurinia Pharmaceuticals Inc [AUPH]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc [AUPH] shares currently have an operating margin of 21.26% and a Gross Margin at 88.24%. Aurinia Pharmaceuticals Inc’s Net Margin is presently recorded at 16.11%.
Aurinia Pharmaceuticals Inc (AUPH) Capital Structure & Debt Analysis
According to recent financial data for Aurinia Pharmaceuticals Inc. ( AUPH), the Return on Equity (ROE) stands at 11.23%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 7.80%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Aurinia Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is 9.66%, showcasing its effectiveness in deploying capital for earnings.
Aurinia Pharmaceuticals Inc (AUPH) Efficiency & Liquidity Metrics
Based on Aurinia Pharmaceuticals Inc’s (AUPH) latest financial statements, the Debt-to-Equity Ratio is 0.22%, indicating its reliance on debt financing relative to shareholder equity.
Aurinia Pharmaceuticals Inc (AUPH) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Aurinia Pharmaceuticals Inc. (AUPH) effectively leverages its workforce, generating an average of $306538.46 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.93% and a Quick Ratio of 5.26%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Aurinia Pharmaceuticals Inc [AUPH]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AUPH. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aurinia Pharmaceuticals Inc go to 189.20%.
Insider trade positions for Aurinia Pharmaceuticals Inc [AUPH]
There are presently around $47.29%, or 52.01%% of AUPH stock, in the hands of institutional investors. The top three institutional holders of AUPH stocks are: ARMISTICE CAPITAL, LLC with ownership of 11.14 million shares, which is approximately 7.7696%. BLACKROCK INC., holding 9.27 million shares of the stock with an approximate value of $$52.94 million in AUPH stocks shares; and BLACKROCK INC., currently with $$22.67 million in AUPH stock with ownership which is approximately 2.7698%.
